Clinical Trial Update: A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial update on retreatment with a combination of nivolumab and ipilimumab in advanced renal cell carcinoma; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Renal Cell Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2023-01-10